抗生素市場規模、佔有率、成長分析、按藥物類別、按應用、按作用機制、按藥物來源、按活性頻譜、按給藥途徑、按地區 - 行業預測 2025-2032

2023 年抗生素市場規模價值 452 億美元，預計將從 2024 年的 473.7 億美元成長到 2032 年的 689.3 億美元，預測期內（2025-2032 年）的複合年成長率為 4.8%。

全球醫藥市場正在經歷重大進步，特別是在創新配方、聯合治療和新作用機制領域。這些創新對於解決日益嚴重的抗生素抗藥性和適應不斷演變的微生物威脅所帶來的挑戰至關重要，並透過強大的研發努力展示了公司對感染疾病預防的奉獻精神。艾伯維、輝瑞、諾華、默克和梯瓦等大公司都在積極進行併購，以擴大其地理影響力並開發新市場。此外，臨床試驗和監管應用的投資顯著增加，提高了抗生素開發的成本。此外，透過開發先進的抗菌配方，產品範圍顯著擴大，顯示人們正在不斷努力克服抗菌抗藥性和改善治療效果。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

抗生素市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 頭孢菌素類
• 青黴素
• Fluoroquinolones
• 大環內酯類
• 卡巴培南類
• Aminoglycosides
• 磺胺類藥物
• 7-ACA
• 其他

抗生素市場規模：按應用和複合年成長率（2025-2032）

• 市場概覽
• 皮膚感染疾病
• 尿道感染
• 耳部感染疾病
• 敗血症
• 呼吸道感染疾病
• 胃腸道感染疾病

抗生素市場規模（按作用機制和複合年成長率） (2025-2032)

• 市場概覽
• 細胞壁合成抑制劑
• 蛋白質合成抑制劑
• DNA合成抑制劑
• RNA合成抑制劑
• 肌酸抑制劑
• 其他

抗生素市場規模（按藥物來源和複合年成長率） (2025-2032)

• 市場概覽
• 自然的
• 合成

抗生素市場規模（按活動頻譜和複合年成長率） (2025-2032)

• 市場概覽
• 頻譜抗生素
• 窄效抗生素

抗生素市場規模（依給藥途徑和複合年成長率） (2025-2032)

• 口服
• 腸外

抗生素市場規模（依通路分類）及複合年成長率（2025-2032）

• 市場概覽
• 零售藥局
• 網路藥局
• 醫院
• 診所

抗生素市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.（US）
• GlaxoSmithKline plc.（GSK）（UK）
• Merck & Co., Inc.（US）
• Novartis AG（Switzerland）
• Johnson & Johnson（US）
• F. Hoffmann-La Roche AG（Switzerland）
• AstraZeneca PLC（UK）
• Bayer AG（Germany）
• Abbott Laboratories（US）
• Eli Lilly and Company（US）
• Bristol-Myers Squibb Company（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Astellas Pharma Inc.（Japan）
• Cipla Ltd（India）
• AbbVie, Inc.（US）
• Lupin Pharmaceuticals, Inc.（US）
• Viatris, Inc.（US）
• Cipla, Inc.（US）
• Shionogi & Co., Ltd.（Japan）
• KYORIN Pharmaceutical Co., Ltd.（Japan）
• Nabriva Therapeutics PLC（Ireland）

結論和建議

Antibiotics Market size was valued at USD 45.2 billion in 2023 and is poised to grow from USD 47.37 billion in 2024 to USD 68.93 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The global pharmaceutical market is witnessing significant advancements, particularly in the realm of innovative drug formulations, combination therapies, and novel mechanisms of action. These innovations are crucial for addressing rising antibiotic resistance and adapting to challenges posed by evolving microbial threats, showcasing companies' dedication to infectious disease prevention through robust research and development efforts. Major players like AbbVie, Pfizer, Novartis, Merck, and Teva are actively engaging in mergers and acquisitions to expand their geographical presence and explore new markets. Additionally, there is a marked increase in investments in clinical trials and regulatory submissions, escalating the cost of antibiotic development. The market is also experiencing notable product expansion driven by the creation of advanced antimicrobial formulations, demonstrating an ongoing commitment to overcoming antimicrobial resistance and enhancing therapeutic efficacy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antibiotics Market Segments Analysis

Global Antibiotics Market is segmented by Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA and Others. Based on Application, the market is segmented into Skin infections, Urinary tract infection, Ear infection, Septicemia, Respiratory infections and Gastrointestinal infections. Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors and Others. Based on Drug Origin, the market is segmented into Natural and Synthetic. Based on Spectrum Of Activity, the market is segmented into Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic, By Route of Administration, Oral and Parenteral. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Distribution Channel, the market is segmented into Retail pharmacies, Online pharmacies, Hospitals and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antibiotics Market

The antibiotics market is significantly driven by the rising prevalence of infectious diseases worldwide. Conditions such as respiratory infections, tuberculosis, urinary tract infections, and sexually transmitted diseases have seen a marked increase in cases, compounded by the growing concern of multidrug resistance. As new and more resistant bacterial strains emerge, healthcare professionals are under pressure to find effective antibiotic solutions to address these evolving challenges. This persistent demand for potent antibiotics to combat infections is a primary factor fueling the growth of the antibiotics market, highlighting the critical need for advancements in the development of these essential medications.

Restraints in the Antibiotics Market

A significant constraint on the antibiotics market is the escalating issue of antibiotic resistance. The proliferation of antibiotic use and misuse among humans and livestock has led to an alarming number of bacteria developing resistance to many current antibiotics. The World Health Organization (WHO) has identified antimicrobial resistance as a critical public health concern. As resistance continues to increase, the pool of effective antibiotics diminishes, posing challenges for the development of new treatments. This scenario not only restricts the application of existing antibiotics but also hampers market growth, necessitating substantial investment in research and development to combat this urgent problem.

Market Trends of the Antibiotics Market

The antibiotics market is witnessing a significant trend towards the increased focus on narrow-spectrum antibiotics, driven by the rising concern over antibiotic resistance and the side effects associated with broad-spectrum alternatives. As healthcare professionals prioritize targeted therapies that specifically address pathogenic bacteria, narrow-spectrum drugs are gaining traction for their ability to minimize collateral damage to beneficial microbiota. This shift not only enhances treatment efficacy but also plays a crucial role in conserving the effectiveness of existing antibiotics by reducing the potential for resistance development. Consequently, pharmaceutical companies are increasingly investing in research and development of narrow-spectrum formulations, shaping the future landscape of antibiotic therapy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Antibiotics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolide
• Carbapenem
• Aminoglycoside
• Sulfonamide
• 7-ACA
• Others

Global Antibiotics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Skin infections
• Urinary tract infection
• Ear infection
• Septicemia
• Respiratory infections
• Gastrointestinal infections

Global Antibiotics Market Size by Action Mechanism & CAGR (2025-2032)

• Market Overview
• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others

Global Antibiotics Market Size by Drug Origin & CAGR (2025-2032)

• Market Overview
• Natural
• Synthetic

Global Antibiotics Market Size by Spectrum Of Activity & CAGR (2025-2032)

• Market Overview
• Broad-spectrum Antibiotic
• Narrow-spectrum Antibiotic

Global Antibiotics Market Size by Route of Administration & CAGR (2025-2032)

• Oral
• Parenteral

Global Antibiotics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail pharmacies
• Online pharmacies
• Hospitals
• Clinics

Global Antibiotics Market Size & CAGR (2025-2032)

• North America (Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel)

US

Canada

• Europe (Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel)

Germany

Spain

France

UK

Italy

Rest of Europe

• Asia Pacific (Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel)

China

India

Japan

South Korea

Rest of Asia-Pacific

• Latin America (Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel)

Brazil

Rest of Latin America

• Middle East & Africa (Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KYORIN Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations